Neuralink, Elon Musk's brain-computer interface company, raises $205M Series C led by Vy Capital, with GV and others participating
Abner Li / 9to5Google :
Context & Ripple Effects
Neuralink's $205M Series C marks the point where the company graduated from its $27M seed-era SEC filing in 2017 into institutional-scale financing, with Vy Capital leading and GV coming in alongside. The raise sits mid-way along an escalation curve that continued with the $280M Series D led by Founders Fund and the $650M Series E at a reported ~$9B pre-money valuation.
What makes this round notable in hindsight is who built on top of it: co-founder Max Hodak's Science Corp later raised $100M+ from Khosla Ventures for a competing retina and brain implant system, while China's Gestala raised $21.6M at a far smaller valuation — showing how quickly the category Neuralink legitimized attracted capital on both sides of the Pacific.
First-order effects
- Vy Capital takes the lead position and GV enters the cap table, giving Neuralink the runway to push brain-computer interface development in the U.S. beyond the small-team scale implied by its 2017 filing.
Second-order effects
- The round validates BCI as a fundable category for other backers: Founders Fund doubled down in the next round, Khosla backed Hodak's rival Science Corp, and Guosheng Capital and Dalton Venture seeded a Chinese counterpart in Gestala — capital now chases multiple horses in the same race rather than Neuralink alone.
Third-order effects
- If the pattern holds, BCI follows the same structure as other Musk-adjacent frontier hardware: rounds escalate by multiples ($27M to $650M across the corpus), investor syndicates broaden each round, and the field consolidates around a few heavily capitalized U.S. players with smaller national-champion efforts elsewhere.
The trend: Brain-computer interfaces are following the frontier-lab capital pattern, where each successive round multiplies the last and concentrates backing around a handful of Musk-adjacent hardware bets.